DNA Repair Gene and MTHFR Gene Polymorphisms as Prognostic Markers in Locally Advanced Adenocarcinoma of the Esophagus or Stomach Treated with Cisplatin and 5-Fluorouracil-Based Neoadjuvant Chemotherapy
Background DNA repair plays an important role in chemoresistance to platinum-based therapy, and therefore polymorphisms in the genes may modulate therapeutic response. We assessed 12 polymorphisms in 7 DNA repair genes and 2 polymorphisms in the MTHFR gene for association with disease response and p...
Gespeichert in:
Veröffentlicht in: | Annals of surgical oncology 2011-09, Vol.18 (9), p.2688-2698 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
DNA repair plays an important role in chemoresistance to platinum-based therapy, and therefore polymorphisms in the genes may modulate therapeutic response. We assessed 12 polymorphisms in 7 DNA repair genes and 2 polymorphisms in the
MTHFR
gene for association with disease response and prognosis.
Methods
A total of 258 patients included in the study had adenocarcinoma of the esophagus (
n
= 114) or gastric cancer (
n
= 144), at stage cT3/4 and cM0, and had been treated with platinum-based neoadjuvant polychemotherapy. The patients were genotyped for polymorphisms in the
XPC
,
XPD
,
XPG
,
APEX
,
XRCC1
,
NBS1
,
XRCC3
, and
MTHFR
genes by the allelic discrimination method and the data correlated with various clinical parameters.
Results
None of the investigated polymorphisms was associated with histopathological response.
XRCC3
polymorphisms rs861539 (
P
= 0.02) and rs861530 (
P
= 0.05) showed association with clinical response in gastric cancer. The variants in
XRCC3
(rs861539,
P
= 0.05; rs1799794,
P
= 0.03) and
MTHFR
(rs1801131,
P
= 0.02) were associated with survival in esophageal and gastric cancer, respectively. In R0 resected patients,
XRCC3
variants (rs861539,
P
= 0.04; rs861530,
P
= 0.02) in esophageal cancer, and
XRCC3
(rs1799794,
P
= 0.02) and
MTHFR
(rs1801131,
P
= 0.005) in gastric cancer predicted survival. Cox regression revealed ypT category (
P
= 0.001) and lymphatic vessel invasion (
P
= 0.03) to be independent prognostic factors for esophageal cancer, and histopathological response (
P
= 0.01),
MTHFR
variant (rs1801131,
P
= 0.002), and ypN category (
P
= 0.02) to be prognostic factors for gastric cancer.
Conclusion
In gastric cancer patients,
MTHFR
variant (rs1801131) could serve as a potential prognostic marker. In esophageal cancer patients, none of the polymorphisms studied had conclusive results in multivariate analysis, although
XRCC3
variant (rs861539) showed an effect on survival in Kaplan–Meier univariate analysis. |
---|---|
ISSN: | 1068-9265 1534-4681 |
DOI: | 10.1245/s10434-011-1601-y |